Loading…

Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166

Saved in:

Bibliographic Details
Published in:	Journal of medical economics 2024-01, Vol.27 (1), p.800
Main Authors:	Pedone, Maria Paola, Dobreva, Miryana, Bastian, Mike, Tavi, Jules, Noonan, Kerry
Format:	Article
Language:	English
Subjects:	Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Azetidines - economics Azetidines - therapeutic use Cost-Benefit Analysis Cost-Effectiveness Analysis Dermatitis, Atopic - drug therapy Dermatitis, Atopic - economics Humans Italy Purines - economics Purines - therapeutic use Pyrazoles - economics Pyrazoles - therapeutic use Severity of Illness Index Sulfonamides - economics Sulfonamides - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!